No Data
Regent Pacific to Change Hong Kong Share Registrar
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
Hong Kong stock announcement to uncover opportunities | SHOUCHENG intends to sell approximately 0.607 billion shares of SHOUGANG RES for about 1.4566 billion Hong Kong dollars.
IDREAMSKY (01119) has reached a collaboration with stc play in the fields of technology and gaming. ASCLETIS-B (01672): The weight loss candidate drug ASC47, which treats obesity, has shown better weight loss effects than single-agent semaglutide in preclinical models when used in combination.
Regent Pacific's Strategic Partners Submits NDA for Premature Ejaculation Drug in China
REGENT PACIFIC (00575.HK) submitted a new drug application for Senstend to the National Medical Products Administration of China.
Gelonghui reported on December 18 that REGENT PACIFIC (00575.HK) announced that the company's strategic business partner Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. ("Jiangsu Wanbang Pharmaceutical", a wholly-owned subsidiary of Shanghai FOSUN PHARMA ("FOSUN")) submitted new drug application registration documents to the National Medical Products Administration on December 17, 2024, and approval is expected within 12 months from the submission date.
Express News | Regent Pacific Group Ltd - Submission of Senstend New Drug Application to Nmpa in China
